Proteomic profiling of brain organoids and extracellular vesicles identifies early Alzheimer's disease biomarkers and drug response heterogeneity

Key Points

• The study aims to identify early biomarkers for Alzheimer's disease and explore drug response variability using brain organoids and extracellular vesicles.
• Utilized brain organoids and extracellular vesicles as models for Alzheimer's disease
• Performed proteomic profiling to analyze biomarker presence and treatment responses
• Integrated organoid and EV data for systems-level understanding
• Identified specific biomarkers associated with early stages of Alzheimer's disease
• Demonstrated variability in drug responses among different organoid models
• Proposed the dual-platform model as a cost-effective approach for precision medicine

Abstract